Thrombocytosis is a recognised feature of -a) Myelofibrosisb) Systemic lupus erythematosisc) Azidothymidine therapy d) Myelodysplastic syndrome

**Core Concept**
Thrombocytosis refers to an elevated platelet count in the peripheral blood, which can be primary (essential) or secondary to various underlying conditions. This condition can result from increased platelet production, decreased platelet destruction, or splenic sequestration.

**Why the Correct Answer is Right**
Myelofibrosis is a type of myeloproliferative neoplasm characterized by the progressive replacement of bone marrow with fibrotic tissue, leading to ineffective hematopoiesis and extramedullary hematopoiesis. This process can result in the overproduction of platelets, manifesting as thrombocytosis. The pathophysiology involves the activation of bone marrow stroma, leading to the release of fibrogenic cytokines and the accumulation of collagen fibers, which disrupt normal hematopoiesis.

**Why Each Wrong Option is Incorrect**
**Option B:** Systemic lupus erythematosus (SLE) is an autoimmune disease that can cause thrombocytopenia (low platelet count) due to immune-mediated platelet destruction, not thrombocytosis.

**Option C:** Azidothymidine (AZT) therapy is used in the treatment of HIV infection and can cause bone marrow suppression, leading to cytopenias (low blood cell counts), including thrombocytopenia.

**Option D:** Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder characterized by ineffective hematopoiesis, leading to cytopenias, including anemia, neutropenia, and thrombocytopenia, but not thrombocytosis.

**Clinical Pearl / High-Yield Fact**
Thrombocytosis can be a diagnostic clue for myeloproliferative neoplasms, including myelofibrosis, and warrants further investigation with bone marrow biopsy and molecular studies to confirm the diagnosis.

**Correct Answer:** D. Myelodysplastic syndrome